Acción BGLC BIONEXUS GENE LAB CORPORATION
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas BioNexus Gene Lab Corporation Other OTC

Acciones

BGLC

US0906281086

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
BioNexus Gene Lab Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
BioNexus Gene Lab : Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare - Form 8-K
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
BioNexus Gene Lab : Submission of Matters to a Vote of Security Holders - Form 8-K
BioNexus Gene Lab Corp. Provides Information to Shareholders
Certain Common Stock of BioNexus Gene Lab Corp. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.
Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp
BioNexus Gene Lab Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bionexus Gene Lab Corp. Announces Resignation of Wei Li Leong as Chief Financial Officer
BioNexus Gene Lab Names Chi Yuen Leong as CEO
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as A Director
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Board of Directors
BioNexus Gene Lab Corp. Announces Executive Changes
Top Premarket Gainers
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
BioNexus Gene Lab Raises $5.8 Million from Public Share Offering
BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BGLC
  4. Acción BGLC
  5. Noticias BioNexus Gene Lab Corporation
  6. Otros idiomas